Signal #134424 · SEC 8-K

$MBRX SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $MBRX filing catalyst

Why did $MBRX trigger an AI stock catalyst alert?

$MBRX triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: Moleculin Biotech Reports Positive Phase 2/3 Interim Data for Annamycin in AML. Key points: - Phase 2/3 trial interim evaluation shows complete remission rates of 43% and 36% vs. 12% for placebo in first 45 patients. - No cardiotoxicity observed; DMC recommended trial continue without modifications. - Data accepted for presentation at the ASH Annual Meeting.

How did $MBRX stock react after the SEC filing?

After the SEC 8-K for $MBRX, observed market reaction: T0 price $8.46. Past moves do not guarantee future results.

Where can I get real-time $MBRX SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $MBRX via Telegram and the VIP Web Terminal from €10/month.

$MBRX

$MBRX – Moleculin Biotech Reports Positive Phase 2/3 Interim Data for Annamycin in AML

Moleculin Biotech, Inc.

2026-11-04 00:00:00 UTC · SEC 8-K · All $MBRX

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+6.5 / 10)

Phase 2/3 trial interim evaluation shows complete remission rates of 43% and 36% vs. 12% for placebo in first 45 patients.
No cardiotoxicity observed; DMC recommended trial continue without modifications.
Data accepted for presentation at the ASH Annual Meeting.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →